We are live on ! Find out more
PNT

POINT Biopharma Global Inc. Common Stock
PNT

Delisted

PNT was delisted on the 26th of December, 2023.

Back to rankings

1 hedge funds and large institutions have $1K invested in POINT Biopharma Global Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 124 closing their positions.

New
Increased
Maintained
Reduced
Closed

18,472% more call options, than puts

Call options by funds: $8.54M | Put options by funds: $46K

99% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 124

99% less funds holding

Funds holding: 125 → 1 (-124)

100% less capital invested

Capital invested by funds: $411M → $1K (-$411M)

Holders
1
Holders Change
-124
Holders Change %
-99.2%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
124
Calls
$8.54M
Puts
$46K
Net Calls
+$8.5M
Net Calls Change
+$9.58M

Top Buyers

Rank Fund Capital Flow
1
BTI
Blue Trust Inc
Georgia
+$1.65K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$70.5M
2
BlackRock
BlackRock
New York
-$44.3M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$31.1M
4
State Street
State Street
Massachusetts
-$23.5M
5
GPP
Great Point Partners
Connecticut
-$19.4M

PNT Hedge Fund Activity: Q4 2023 in Review

1 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q4 2023, worth a combined $1K — down 100% from $411M a quarter earlier.

Sellers outnumbered buyers: 124 funds closed out of PNT and 1 opened new positions — a net loss of 123 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Blue Trust Inc, opening a new position worth an estimated $1.65K. The largest seller was BVF Inc, exiting entirely with an estimated $70.5M sold.

  • 1 institutional investor held POINT Biopharma Global Inc. Common Stock (PNT) as of Q4 2023, down from 125 in Q3 2023.
  • Funds reported $1K of POINT Biopharma Global Inc. Common Stock stock for Q4 2023, down 100% quarter-over-quarter.
  • 1 fund opened new POINT Biopharma Global Inc. Common Stock positions in Q4 2023 and 124 closed out, a net change of -123 holders.
  • The largest POINT Biopharma Global Inc. Common Stock buyer in Q4 2023 was Blue Trust Inc, an estimated $1.65K added.
  • The largest POINT Biopharma Global Inc. Common Stock seller in Q4 2023 was BVF Inc, an estimated $70.5M sold.

Based on aggregated 13F filings for Q4 2023.